

MINISTRY OF HEALTH

PHARMACY AND POISONS BOARD

PUBLIC ALERT ON FALSIFIED OZEMPIC (SEMAGLUTIDE) PENS

The Pharmacy and Poisons Board "the board" wishes to draw the attention of the public to an alert received from the INTERPOL concerning the falsification of Ozempic Pens (Semaglutide) where Apidra Solostar pens (glulisine) used to treat both type 1 and type 2 diabetes has been falsely relabelled as Ozempic (Semaglutide) Pens.

Consequently, the Board would like to inform the public that Ozempic Pens are currently NOT registered or authorized by the Board to be placed in the Kenyan market. Therefore, any product being marketed as Ozempic Pens is illegally in the market and the Board cannot ascertain their safety, quality and effectiveness.

To safeguard public safety, the Board has initiated a rapid response and heightened surveillance to verify whether the falsified Ozempic (Semaglutide) Pens is presently circulating in the Kenyan market.

The Board cautions the public and healthcare professionals AGAINST trading, distribution, wholesaling, retailing, issuing, dispensing, use or administration to patients of the falsified Ozempic (Semaglutide) Pens, as such actions are illegal and jeopardise public health and safety.

We encourage the public and healthcare professionals to immediately share any information regarding Ozempic pens with the Pharmacy and Poisons Board.

The Board remains committed to protecting the health of the public and encourages the public to remain vigilant at all times and promptly report any suspected cases of sub-standard/falsified health products or adverse drug reactions. The reports may be made to the nearest healthcare facility or the Pharmacy and Poisons Board through the following channels:

- https://pv.pharmacyboardkenya.org/users/mpublic;
- Mobile application: mPvERS both Android & iOS;
- USSD code: at *271# or
- Email: pms@ppb.go.ke or Tel No. 0795743049

Dr. F. M. Siyoi

CHIEF EXECUTIVE OFFICER

17th July, 2024

PHOTOS

Genuine Ozempic Pens



Falsified Ozempic Pen

